410 Medical, of Durham, N.C., won a group purchasing agreement for emergency medicine products with Premier Inc. Effective Oct. 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for 410 Medical's Lifeflow product.
The Centers for Disease Control and Prevention awarded a two-year, $988,300 small business innovation research contract to Aptagen LLC, of Jacobus, Pa., to develop an aptamer-based diagnostic for human carriers of the pork tapeworm, Taenia solium. This diagnostic will aim to help prevent Neurocysticercosis, the leading cause of adult-onset epilepsy in the developing world.
Apteryx Imaging Inc., of Vancouver, British Columbia, reported a contract awarded to its wholly owned subsidiary, Apteryx Inc., for the Defense Logistics Agency electronic catalog. It has a notional maximum contract amount of $20.9 million and provides Apteryx the ability to serve as a preferred supplier of dental imaging products, software and services. The company said that there is no minimum purchase obligation under the contract.
Cellex GmbH has opened a new cell manufacturing plant in Cologne, Germany, that will be the focal point for the production of cell therapy products as targeted treatments for different types of cancers and other diseases.
Highmark Interactive, of Mississauga, Ontario, plans to begin therapeutic trials using its FDA-cleared EQ Brain Performance software platform. The announcement of their intention to formally begin studying the therapeutic impact of their digital platform represents a first for gamified neurological solutions, further solidifying their position as leaders in the digital medicine industry. The company intends to begin their trials using its EQ Active product, which focuses on treating patients suffering from concussion.
Nemaura Medical Inc., of Loughborough, U.K., expanded its Sugarbeat continuous glucose monitor capabilities by launching a new digital health offering, Beat Diabetes (www.BEATdiabetes.life), which focuses on the prevention and reversal of type 2 diabetes through a range of holistic app and coaching services encouraging behavioral change.
Nijmegen, Netherlands-based Enzyre, which is developing an ambulant diagnostic technology for coagulation testing, entered a research collaboration agreement with Tokyo-based Takeda Pharmaceutical Co. Ltd. to develop a diagnostic device that will enable hemophilia patients to determine their coagulation status at home.
Titan Medical Inc., of Toronto, received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement. At the same time, the company received notification from the Nasdaq Listing Qualifications Department that it was not in compliance with the minimum market value of listed securities of US$35 million requirement. These notifications do not impact the company’s listing on the Nasdaq Capital Market at this time.
Zionexa, of Paris, and Petnet Solutions Inc., a unit of a wholly owned subsidiary of Siemens Medical Solutions USA Inc., of Malvern, Pa., have entered an exclusive agreement for the manufacturing and distribution of Zionexa’s new PET diagnostic drug, Fluoroestradiol, which is pending approval by the U.S. FDA.